DUPIXENT® is indicated as an add-on maintenance treatment of adult and pediatric patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT® is not indicated for the relief of acute bronchospasm or status asthmaticus.

DUPIXENT® (dupilumab) inhibits signaling of both IL-4 and IL-13, two Type 2 cytokines that contribute to inflammation in moderate-to-severe atopic dermatitis that is uncontrolled. The mechanism of dupilumab action has not been definitively established. Learn about DUPIXENT® mechanism of action (MOA). Serious adverse reactions may occur.

DUPIXENT® (dupilumab) inhibits signaling of both IL-4 and IL-13, of the two key drivers of type 2 inflammation in eosinophilic esophagitis (EoE). Learn about DUPIXENT® mechanism of action (MOA). Serious adverse reactions may occur. Please see Important Safety Information and full …

DUPIXENT targets both IL-4 and IL-13 signaling, two of the key sources of type 2 inflammation in COPD. The mechanism of dupilumab action has not been definitively established. 16-20. DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled COPD and an eosinophilic phenotype. 1

Review the DUPIXENT® (dupilumab) mechanism of action (MOA) for CRSwNP. DUPIXENT® is the first and only dual inhibitor of IL-4 and IL-13 signaling, inhibiting two of the key sources of type 2 inflammation.

DUPIXENT® is indicated as an add-on maintenance treatment of adult and pediatric patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT® is not indicated for the relief of acute bronchospasm or status asthmaticus.

DUPIXENT. MOA: Mechanism of Action Real DUPIXENT Patients Peer Videos Case Studies Frequently Asked Questions Efficacy and Safety. Efficacy and Safety Overview Study Designs WI-NRS Results IGA PN-S Results Composite Endpoint Safety Profile Dosage and Administration; Patient Support Program. DUPIXENT MyWay ® Program Overview Patient …

DUPIXENT. MOA: Mechanism of Action Identifying Patients Frequently Asked Questions EFFICACY AND SAFETY. Efficacy and Safety Overview Efficacy Safety Data Study Designs DOSAGE AND ADMINISTRATION; PATIENT SUPPORT PROGRAM. DUPIXENT MyWay® Program Overview Patient Enrollment Insurance Coverage Support Copay and Patient Access …

DUPIXENT. MOA: Mechanism of Action Identifying Patients Frequently Asked Questions EFFICACY AND SAFETY. Efficacy and Safety Overview Efficacy Safety Data Study Designs DOSAGE AND ADMINISTRATION; PATIENT SUPPORT PROGRAM. DUPIXENT MyWay® Program Overview Patient Enrollment Insurance Coverage Support Copay and Patient Access …

Atopic Dermatitis: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.